Discovery of Potent and Orally Effective Dual Janus Kinase 2/FLT3 Inhibitors for the Treatment of Acute Myelogenous Leukemia and Myeloproliferative Neoplasms
Authors:
- 31 October 2019
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 62 (22) , 10305-10320
Abstract
Herein, we describe the design, synthesis, and structure-activity relationships of a series of unique 4-(1H-pyrazol-4-yl)-pyrimidin-2-amine derivatives that selectively inhibit JAK2 and FLT3 kinases. These screening cascades revealed that 18e was a preferred compound, with IC50 values of 0.7 nM and 4 nM for JAK2 and FLT3, respectively. Moreover, 18e was a potent JAK2 inhibitor with 37-fold and 56-fold selectivity over JAK1 and JAK3, respectively, and possessed an excellent selectivity profile over the other 100 representative kinases. In a series of cytokine-stimulated cell-based assays, 18e exhibited a higher JAK2 selectivity than other JAK isoforms. The oral administration of 18e at 60 mg/kg could significantly inhibit tumor growth, with a tumor growth inhibitory rate of 93% and 85% in MV4-11 and SET-2 xenograft models, respectively. Additionally, 18e showed an excellent bioavailability (F = 58%), a suitable half-life time (T1/2 = 4.1 h), a satisfactory metabolic stability and a weak CYP3A4 inhibitory activity, suggesting that 18e might be a potential drug candidate for JAK2-driven myeloproliferative neoplasms and FLT3-ITD driven acute myelogenous leukemia.Keywords
Funding Information
- National Natural Science Foundation of China (81703344, 81673289)
- 1.3.5 Project for Disciplines of Excellence, West China Hospital, Sichuan University
This publication has 45 references indexed in Scilit:
- Roles of JAK2 in Aging, Inflammation, Hematopoiesis and Malignant TransformationCells, 2019
- Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic LeukemiaCancer Cell, 2015
- Targeting the JAK2-STAT5 pathway in CMLBlood, 2014
- JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivoBlood, 2014
- JAK/STAT signaling in hematological malignanciesOncogene, 2012
- Discovery of 1-Amino-5H-pyrido[4,3-b]indol-4-carboxamide Inhibitors of Janus Kinase 2 (JAK2) for the Treatment of Myeloproliferative DisordersJournal of Medicinal Chemistry, 2011
- STATs in cancer inflammation and immunity: a leading role for STAT3Nature Reviews Cancer, 2009
- Regulation of JAK–STAT signalling in the immune systemNature Reviews Immunology, 2003
- TheJanusprotein tyrosine kinases in hematopoietic cytokine signalingSeminars in Immunology, 1995
- Jaks and Stats in signaling by the cytokine receptor superfamilyTrends in Genetics, 1995